Also trades as: SABSW (NASDAQ) · $vol 0M
SABS NASDAQ
SAB Biotherapeutics, Inc.
1W: +6.6%
1M: -4.7%
3M: -11.8%
YTD: -18.6%
1Y: +1.3%
3Y: -68.0%
5Y: -96.9%
$3.07
+0.28 (+10.04%)
Weekly Expected Move ±10.7%
$2
$3
$3
$3
$3
Credit Risk of going bust: lower than 69% of companies Debt: 1.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.7%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.7%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$279.3M
52W Range2.44-5.15
Volume646,572
Avg Volume613,099
Beta0.58
Dividend—
Analyst Ratings
Company Info
CEOSamuel J. Reich
Employees86
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitesab.bio
777 W 41st St.
Miami Beach, FL 33140
US
Miami Beach, FL 33140
US
605 679 6980
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Latest News
375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
12 Health Care Stocks Moving In Monday's Intraday Session
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kropotova Alexandra | F-InKind | 473 | — | 2026-09-17 |
| Kropotova Alexandra | F-InKind | 988 | — | 2026-06-25 |
| Kropotova Alexandra | F-InKind | 988 | — | 2026-03-24 |
| Sullivan Eddie Joe | A-Award | 3,000,000 | $4.45 | 2026-02-03 |
| Reich Samuel J | A-Award | 4,800,000 | $4.45 | 2026-02-03 |